PHS
ALDR

PFM Health Sciences’s Alder Biopharmaceuticals ALDR Stock Holding History

PFM Health Sciences’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,306,367
Closed -$31.5M – 109
2019
Q1 		$31.5M Buy
+2,306,367
New +$29.9M 0.7% 52
2018
Q4 		– Sell
-1,916,664
Closed -$31.9M – 135
2018
Q3 		$31.9M Sell
1,916,664
-289,249
-13% -$5.23M 0.47% 76
2018
Q2 		$34.9M Sell
2,205,913
-290,914
-12% -$4.42M 0.55% 69
2018
Q1 		$31.7M Buy
+2,496,827
New +$36.1M 0.64% 59
2017
Q3 		– Sell
-834,191
Closed -$9.55M – 109
2017
Q2 		$9.55M Sell
834,191
-210,990
-20% -$3.9M 0.26% 80
2017
Q1 		$21.7M Sell
1,045,181
-1,868,770
-64% -$41.4M 0.54% 64
2016
Q4 		$60.6M Buy
2,913,951
+906,287
+45% +$23.6M 1.71% 21
2016
Q3 		$65.8M Sell
2,007,664
-1,891,545
-49% -$57.6M 1.93% 17
2016
Q2 		$97.4M Buy
3,899,209
+356,562
+10% +$9.65M 2.94% 5
2016
Q1 		$86.8M Buy
3,542,647
+1,652,617
+87% +$38.3M 2.68% 10
2015
Q4 		$62.4M Buy
1,890,030
+784,119
+71% +$26.5M 1.9% 20
2015
Q3 		$36.2M Buy
1,105,911
+352,630
+47% +$15M 1.02% 37
2015
Q2 		$39.9M Buy
753,281
+122,815
+19% +$4.47M 1.01% 40
2015
Q1 		$18.2M Buy
630,466
+300,518
+91% +$8.25M 0.5% 61
2014
Q4 		$9.6M Sell
329,948
-704,082
-68% -$12.6M 0.22% 75
2014
Q3 		$13.1M Buy
1,034,030
+296,003
+40% +$4.47M 0.3% 49
2014
Q2 		$14.8M Buy
+738,027
New +$10.4M 0.3% 55

Other funds holding ALDR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PFM Health Sciences's ALDR Position: Q2 2019 in Review

PFM Health Sciences sold out of Alder Biopharmaceuticals (ALDR) in Q2 2019, closing a stake of 2,306,367 shares — an estimated $31.5M sold.

PFM Health Sciences first reported a position in ALDR in Q2 2014 and held it in 17 quarters. The position peaked at $97.4M in Q2 2016. 127 funds tracked by Wall St. Rank hold ALDR as of Q2 2019.

  • PFM Health Sciences reported no remaining Alder Biopharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • PFM Health Sciences sold 2,306,367 Alder Biopharmaceuticals shares in Q2 2019, an estimated $31.5M.
  • PFM Health Sciences first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 17 quarters.
  • PFM Health Sciences's Alder Biopharmaceuticals position peaked at $97.4M in Q2 2016.
  • 127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2019.

Based on PFM Health Sciences's 13F filing for Q2 2019, filed 14 Aug 2019.